Gastro-intestinal drugs development company AGI Therapeutics has completed patient enrolment for a phase III clinical trial for its drug Rezular, a treatment for irritable bowel syndrome.
As part of its Ardis 1 trial over 700 randomised patients at 123 clinical centres in the US will take the drug for 12 weeks. The company is expected to announce the results of this trial before June.
Dr John Devane, AGI chief executive said the company was on course for recruitment to a further Phase III study designed to assess the safety of the drug for patients taking the drug for 12 months.
Phase III studies of the drug has been under way since October and these human trials are the last hurdle to be crossed before a drug is considered for final approval.